Rocky Hill, CT, United States of America

Andrew P Degnan

USPTO Granted Patents = 19 

 

 

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 64(Granted Patents)


Location History:

  • New Haven, CT (US) (2007 - 2010)
  • Rocky Hill, CT (US) (2008 - 2017)
  • Jamison, PA (US) (2019 - 2023)

Company Filing History:


Years Active: 2007-2025

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):

Title: The Innovative Contributions of Andrew P Degnan

Introduction

Andrew P Degnan is a notable inventor based in Rocky Hill, CT (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 18 patents to his name, Degnan has made strides in developing compounds that target various disorders of the central nervous system and other medical conditions.

Latest Patents

Among his latest patents, Degnan has developed oxazolidinones as modulators of mGluR5. This patent relates to compounds that serve as ligands, agonists, and partial agonists for the mGluR5 receptor, which may be beneficial in treating various central nervous system disorders. Another significant patent involves compounds useful as inhibitors of Helios protein. These compounds are designed to inhibit Helios protein and are applicable in treating viral infections and proliferative disorders, such as cancer.

Career Highlights

Degnan has had a distinguished career, working with prominent companies such as Bristol-Myers Squibb Company. His work has focused on innovative pharmaceutical solutions that address critical health issues.

Collaborations

Throughout his career, Degnan has collaborated with esteemed colleagues, including John E Macor and George O Tora. These partnerships have contributed to the advancement of his research and the development of his patented compounds.

Conclusion

Andrew P Degnan's innovative work in pharmaceuticals has led to the development of important compounds that hold promise for treating various medical conditions. His contributions continue to impact the field significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…